Tiziana Life Sciences Ltd is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Pharmaceutical Preparations.
The next scheduled catalyst is A Phase 2a Study of Foralumab Nasal in Patients With Multiple System Atrophy (MSA) on April 1, 2027. There are 2 upcoming events on record.
Across 8 concluded trials, 25% reached completion rather than being terminated or withdrawn.
Trial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.